NHS patients in Scotland with the rare disease atypical haemolytic uremic syndrome (aHUS) will now be able to access treatment with Alexion's Ultomiris, ahead of their counterparts in England and ...
and cardiovascular disease is the most common cause of death in these patients. 4D-310 continues to be well tolerated, with the previously reported cases of aHUS having fully resolved and no new ...
Eculizumab is under clinical development by Alexion Pharmaceuticals and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Associated Acute Lung Injury.